Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Insight Molecular Diagnostics (IMDX) Construction in Progress (2019 - 2026)

Insight Molecular Diagnostics' Construction in Progress history spans 7 years, with the latest figure at $765000.0 for Q4 2025.

  • On a quarterly basis, Construction in Progress rose 125.0% to $765000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $765000.0, a 125.0% increase, with the full-year FY2025 number at $765000.0, up 125.0% from a year prior.
  • Construction in Progress hit $765000.0 in Q4 2025 for Insight Molecular Diagnostics, up from $685000.0 in the prior quarter.
  • Over the last five years, Construction in Progress for IMDX hit a ceiling of $3.1 million in Q1 2022 and a floor of $263000.0 in Q2 2025.
  • Historically, Construction in Progress has averaged $1.1 million across 5 years, with a median of $696500.0 in 2023.
  • Biggest five-year swings in Construction in Progress: tumbled 85.83% in 2021 and later soared 730.52% in 2022.
  • Tracing IMDX's Construction in Progress over 5 years: stood at $1.2 million in 2021, then surged by 72.3% to $2.1 million in 2022, then crashed by 66.07% to $726000.0 in 2023, then plummeted by 53.17% to $340000.0 in 2024, then surged by 125.0% to $765000.0 in 2025.
  • Business Quant data shows Construction in Progress for IMDX at $765000.0 in Q4 2025, $685000.0 in Q3 2025, and $263000.0 in Q2 2025.